Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance
dc.contributor.author | Deshmukh, Shivprasad S. | |
dc.contributor.author | Paradkar, Anant R | |
dc.contributor.author | Abrahmsén-Alami, S. | |
dc.contributor.author | Govender, R. | |
dc.contributor.author | Viridén, A. | |
dc.contributor.author | Winge, F. | |
dc.contributor.author | Matic, H. | |
dc.contributor.author | Booth, J. | |
dc.contributor.author | Kelly, Adrian L. | |
dc.date.accessioned | 2020-10-26T11:16:08Z | |
dc.date.accessioned | 2020-11-05T11:36:50Z | |
dc.date.available | 2020-10-26T11:16:08Z | |
dc.date.available | 2020-11-05T11:36:50Z | |
dc.date.issued | 2020-02 | |
dc.identifier.citation | Deshmukh S, Paradkar A, Abrahmsén-Alami S et al (2020) Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance. International Journal of Pharmaceutics. 575: 118908. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/18155 | |
dc.description | Yes | en_US |
dc.description.abstract | A study has been carried out to investigate controlled release performance of caplet shaped injection moulded (IM) amorphous solid dispersion (ASD) tablets based on the model drug AZD0837 and polyethylene oxide (PEO). The physical/chemical storage stability and release robustness of the IM tablets were characterized and compared to that of conventional extended release (ER) hydrophilic matrix tablets of the same raw materials and compositions manufactured via direct compression (DC). To gain an improved understanding of the release mechanisms, the dissolution of both the polymer and the drug were studied. Under conditions where the amount of dissolution media was limited, the controlled release ASD IM tablets demonstrated complete and synchronized release of both PEO and AZD0837 whereas the release of AZD0837 was found to be slower and incomplete from conventional direct compressed ER hydrophilic matrix tablets. Results clearly indicated that AZD0837 remained amorphous throughout the dissolution process and was maintained in a supersaturated state and hence kept stable with the aid of the polymeric carrier when released in a synchronized manner. In addition, it was found that the IM tablets were robust to variation in hydrodynamics of the environment and PEO molecular weight. | en_US |
dc.description.sponsorship | The research was funded by AstraZeneca, Sweden. | en_US |
dc.language.iso | en | en_US |
dc.rights | © 2019 Elsevier B.V. All rights reserved. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. | en_US |
dc.subject | Oral solid dosage (OSD) | en_US |
dc.subject | Polymer release | en_US |
dc.subject | Release robustness | en_US |
dc.subject | Poorly soluble drug | en_US |
dc.subject | Polyethylene oxide (PEO) | en_US |
dc.subject | Hot melt extrusion (HME) | en_US |
dc.subject | Injection moulding (IM) | en_US |
dc.subject | Controlled release | en_US |
dc.subject | Amorphous solid dispersion (ASD) | en_US |
dc.title | Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance | en_US |
dc.status.refereed | Yes | en_US |
dc.date.application | 2019-12-03 | |
dc.type | Article | en_US |
dc.type.version | Accepted manuscript | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.ijpharm.2019.118908 | |
dc.date.updated | 2020-10-26T11:16:15Z | |
refterms.dateFOA | 2020-11-05T11:37:27Z | |
dc.date.accepted | 2019-11-24 |